# BeOne Medicines executive stock transactions

> Live situation record from CLSTR: https://clstr.news/situations/beone-medicines-executive-stock-transactions
> Updated: 2026-08-12T21:23:01.000Z. Sources: 3. Developments: 2.

In July 2026, BeOne Medicines AG CEO John Oyler sold 109,713 American Depositary Shares for approximately $34.6 million. The sale was conducted under a pre-arranged Rule 10b5-1 trading plan. Despite the transaction, Oyler maintained a controlling ownership position in the oncology-focused biopharma company, holding more than 50.4 million shares through various trusts and an investment LLC.

During the same period, institutional ownership of the stock reached about 48.5%. While investor Siren L. L. C. reduced its stake by 7% in the first quarter, other entities including Cetera Investment Advisers, Rhumbline Advisers, Arrowstreet Capital, Invesco Ltd., and EverSource Wealth Advisors added new positions.

## Timeline

### 2026-08-12: Corporate executives and funds execute significant stock transactions

Recent SEC filings reveal significant stock activity, including large-scale sales by BeOne Medicines CEO John Oyler and insider transactions at AppFolio and Omada Health.

3 sources. https://clstr.news/cluster/farmers-merchants-bancorp-director-sells-shares-as-oncolytics-biotech-misses-earnings

### 2026-07-22: BeOne Medicines CEO sells $44.6 M of stock while retaining dominant stake

BeOne Medicines CEO John Oyler sold $34.6 M of stock but still controls over 50 M shares; Siren L. L. C. cut its stake to $138 M, while other investors added new positions.

3 sources. https://clstr.news/cluster/beone-medicines-ceo-sells-446-m-of-stock-while-retaining-dominant-stake

---
Cite as: BeOne Medicines executive stock transactions. CLSTR, https://clstr.news/situations/beone-medicines-executive-stock-transactions